



Clinical trial results:

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (LUCERNE)

Summary

EudraCT number	2018-004042-42
Trial protocol	AT PT DE HU DK ES PL BG IT
Global end of trial date	07 January 2022

Results information

Result version number	v1 (current)
This version publication date	01 January 2023
First version publication date	01 January 2023

Trial information

Trial identification

Sponsor protocol code	GR40844
-----------------------	---------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03823300
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	F. Hoffmann-La Roche, Ltd.
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland,
Public contact	F. Hoffmann-La Roche, Ltd., F. Hoffmann-La Roche, Ltd., +41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche, Ltd., F. Hoffmann-La Roche, Ltd., +41 616878333, global.trial_information@roche.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 January 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 October 2020
Global end of trial reached?	Yes
Global end of trial date	07 January 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial was to evaluate the efficacy and safety of faricimab compared with aflibercept in patients with neovascular age-related macular degeneration.

Protection of trial subjects:

This study was conducted in full conformance with the ICH E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. All participants were required to read and sign an informed consent form prior to participation in the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 March 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 66
Country: Number of subjects enrolled	Australia: 38
Country: Number of subjects enrolled	Austria: 14
Country: Number of subjects enrolled	Brazil: 8
Country: Number of subjects enrolled	Bulgaria: 8
Country: Number of subjects enrolled	Denmark: 7
Country: Number of subjects enrolled	France: 26
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	Hong Kong: 9
Country: Number of subjects enrolled	Hungary: 33
Country: Number of subjects enrolled	Italy: 12
Country: Number of subjects enrolled	Korea, Republic of: 35
Country: Number of subjects enrolled	Poland: 46
Country: Number of subjects enrolled	Portugal: 9
Country: Number of subjects enrolled	Russian Federation: 16
Country: Number of subjects enrolled	Singapore: 5
Country: Number of subjects enrolled	Spain: 22
Country: Number of subjects enrolled	Taiwan: 19
Country: Number of subjects enrolled	Turkey: 12

Country: Number of subjects enrolled	United States: 267
Worldwide total number of subjects	658
EEA total number of subjects	183

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	63
From 65 to 84 years	492
85 years and over	103

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 1012 patients were screened, 354 of whom failed screening, most commonly due to not meeting inclusion criteria. A total of 658 treatment-naive patients with nAMD were randomized 1:1 into the study: 331 to the faricimab arm and 327 to the aflibercept arm.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A: Faricimab

Arm description:

Subjects randomized to Arm A received 6 mg of faricimab intravitreally (IVT) once every 4 weeks (Q4W) up to Week 12 (4 injections). At Week 20, protocol-defined assessment of disease activity required Arm A subjects with active disease to be treated with a once every 8 weeks (Q8W) dosing regimen of 6 mg of faricimab (i.e., at Weeks 20, 28, 36, 44, 52, and 60). A second assessment of disease activity at Week 24 required Arm A subjects with active disease (excluding those with active disease at Week 20) to be treated with a once every 12 weeks (Q12W) dosing regimen of 6 mg of faricimab IVT (i.e., at Weeks 24, 36, 48, and 60). Subjects who did not have active disease at Weeks 20 and 24 were treated with 6 mg of faricimab IVT once every 16 weeks (Q16W; i.e., at Weeks 28, 44, and 60). From Week 60 (when all of Arm A was scheduled to receive study drug) to Week 108, Arm A subjects were to be treated according to a personalized treatment interval (PTI) dosing regimen (Q8W, Q12W, or Q16W).

Arm type	Experimental
Investigational medicinal product name	Faricimab
Investigational medicinal product code	RO6867461
Other name	Vabysmo™, VA2, Humanized anti-VEGF-A anti-Ang-2 bispecific Antibody
Pharmaceutical forms	Solution for injection
Routes of administration	Intravitreal use

Dosage and administration details:

Subjects randomized to Arm A received 6 mg of faricimab intravitreally (IVT) once every 4 weeks (Q4W) up to Week 12 (4 injections). At Week 20, protocol-defined assessment of disease activity required Arm A subjects with active disease to be treated with a once every 8 weeks (Q8W) dosing regimen of 6 mg of faricimab (i.e., at Weeks 20, 28, 36, 44, 52, and 60). A second assessment of disease activity at Week 24 required Arm A subjects with active disease (excluding those with active disease at Week 20) to be treated with a once every 12 weeks (Q12W) dosing regimen of 6 mg of faricimab IVT (i.e., at Weeks 24, 36, 48, and 60). Subjects who did not have active disease at Weeks 20 and 24 were treated with 6 mg of faricimab IVT once every 16 weeks (Q16W; i.e., at Weeks 28, 44, and 60). From Week 60 (when all of Arm A was scheduled to receive study drug) to Week 108, Arm A subjects were to be treated according to a personalized treatment interval (PTI) dosing regimen (Q8W, Q12W, or Q16W).

Arm title	Arm B: Aflibercept
------------------	--------------------

Arm description:

Subjects randomized to the active comparator (Arm B) received a 2-mg dose of aflibercept that was administered intravitreally (IVT) Q8W, after 3 consecutive monthly doses during the 108-week treatment period. Subjects were to receive 15 IVT injections of aflibercept during the 108-week treatment period comprising three initiating injections (2 mg of aflibercept Q4W to Week 8), followed by 12 maintenance injections (2 mg of aflibercept Q8W at Weeks 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, and 104).

Arm type	Active comparator
----------	-------------------

Investigational medicinal product name	Aflibercept
Investigational medicinal product code	
Other name	Eylea
Pharmaceutical forms	Solution for injection
Routes of administration	Intravitreal use

Dosage and administration details:

Subjects randomized to the active comparator (Arm B) received a 2-mg dose of aflibercept that was administered intravitreally (IVT) Q8W, after 3 consecutive monthly doses during the 108-week treatment period. Subjects were to receive 15 IVT injections of aflibercept during the 108-week treatment period comprising three initiating injections (2 mg of aflibercept Q4W to Week 8), followed by 12 maintenance injections (2 mg of aflibercept Q8W at Weeks 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, and 104).

Number of subjects in period 1	Arm A: Faricimab	Arm B: Aflibercept
Started	331	327
Received at Least One Dose of Study Drug	331	326
Completed up to Week 48	321	309
Completed	297	273
Not completed	34	54
Consent withdrawn by subject	16	22
Physician decision	1	7
Adverse event, non-fatal	3	5
Death	10	14
Not Specified	1	-
Not Eligible	-	1
Lost to follow-up	1	3
Lack of efficacy	1	1
Protocol deviation	1	1

Baseline characteristics

Reporting groups

Reporting group title	Arm A: Faricimab
-----------------------	------------------

Reporting group description:

Subjects randomized to Arm A received 6 mg of faricimab intravitreally (IVT) once every 4 weeks (Q4W) up to Week 12 (4 injections). At Week 20, protocol-defined assessment of disease activity required Arm A subjects with active disease to be treated with a once every 8 weeks (Q8W) dosing regimen of 6 mg of faricimab (i.e., at Weeks 20, 28, 36, 44, 52, and 60). A second assessment of disease activity at Week 24 required Arm A subjects with active disease (excluding those with active disease at Week 20) to be treated with a once every 12 weeks (Q12W) dosing regimen of 6 mg of faricimab IVT (i.e., at Weeks 24, 36, 48, and 60). Subjects who did not have active disease at Weeks 20 and 24 were treated with 6 mg of faricimab IVT once every 16 weeks (Q16W; i.e., at Weeks 28, 44, and 60). From Week 60 (when all of Arm A was scheduled to receive study drug) to Week 108, Arm A subjects were to be treated according to a personalized treatment interval (PTI) dosing regimen (Q8W, Q12W, or Q16W).

Reporting group title	Arm B: Aflibercept
-----------------------	--------------------

Reporting group description:

Subjects randomized to the active comparator (Arm B) received a 2-mg dose of aflibercept that was administered intravitreally (IVT) Q8W, after 3 consecutive monthly doses during the 108-week treatment period. Subjects were to receive 15 IVT injections of aflibercept during the 108-week treatment period comprising three initiating injections (2 mg of aflibercept Q4W to Week 8), followed by 12 maintenance injections (2 mg of aflibercept Q8W at Weeks 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, and 104).

Reporting group values	Arm A: Faricimab	Arm B: Aflibercept	Total
Number of subjects	331	327	658
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	30	33	63
From 65-84 years	257	235	492
85 years and over	44	59	103
Age Continuous			
Units: Years			
arithmetic mean	74.8	76.1	
standard deviation	± 8.4	± 8.6	-
Sex: Female, Male			
Units: Participants			
Female	203	188	391
Male	128	139	267
Race/Ethnicity, Customized			
Units: Subjects			
White	278	270	548
Asian	38	34	72
Unknown	12	17	29
Black or African American	2	5	7

American Indian or Alaska Native	1	0	1
Multiple	0	1	1
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	35	46	81
Not Hispanic or Latino	287	274	561
Unknown or Not Reported	9	7	16
Region of Enrollment			
Units: Subjects			
United States and Canada	135	132	267
Asia	35	33	68
Rest of the World	161	162	323
Number of Participants by the Eye (Right or Left) Chosen as the Study Eye			
Units: Subjects			
Right Eye	168	170	338
Left Eye	163	157	320
Number of Participants by the BCVA Letter Score Categories in the Study Eye			
Units: Subjects			
≥74 Letters	45	39	84
73 to 55 Letters	181	183	364
≤54 Letters	105	105	210
Number of Participants by the Low Luminance Deficit (LLD) Letter Score Categories in the Study Eye			
Units: Subjects			
<33 Letters	238	234	472
≥33 Letters	89	93	182
Missing/Invalid	4	0	4
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye by Fundus Fluorescein Angiography			
Units: Subjects			
Occult	171	140	311
Classic	98	109	207
Minimally Classic	30	31	61
Retinal Angiomatous Proliferation (RAP)	14	15	29
Predominantly Classic	6	16	22
Polypoidal Choroidal Vasculopathy (PCV)	5	8	13
Missing	7	8	15
Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye			
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision Vision™ or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R). The BCVA letter score ranges from 0 to 100 (best score attainable), with a higher score indicating better visual acuity.			
Units: ETDRS Letters			
arithmetic mean	58.7	58.9	-
standard deviation	± 14.0	± 13.3	-

End points

End points reporting groups

Reporting group title	Arm A: Faricimab
-----------------------	------------------

Reporting group description:

Subjects randomized to Arm A received 6 mg of faricimab intravitreally (IVT) once every 4 weeks (Q4W) up to Week 12 (4 injections). At Week 20, protocol-defined assessment of disease activity required Arm A subjects with active disease to be treated with a once every 8 weeks (Q8W) dosing regimen of 6 mg of faricimab (i.e., at Weeks 20, 28, 36, 44, 52, and 60). A second assessment of disease activity at Week 24 required Arm A subjects with active disease (excluding those with active disease at Week 20) to be treated with a once every 12 weeks (Q12W) dosing regimen of 6 mg of faricimab IVT (i.e., at Weeks 24, 36, 48, and 60). Subjects who did not have active disease at Weeks 20 and 24 were treated with 6 mg of faricimab IVT once every 16 weeks (Q16W; i.e., at Weeks 28, 44, and 60). From Week 60 (when all of Arm A was scheduled to receive study drug) to Week 108, Arm A subjects were to be treated according to a personalized treatment interval (PTI) dosing regimen (Q8W, Q12W, or Q16W).

Reporting group title	Arm B: Aflibercept
-----------------------	--------------------

Reporting group description:

Subjects randomized to the active comparator (Arm B) received a 2-mg dose of aflibercept that was administered intravitreally (IVT) Q8W, after 3 consecutive monthly doses during the 108-week treatment period. Subjects were to receive 15 IVT injections of aflibercept during the 108-week treatment period comprising three initiating injections (2 mg of aflibercept Q4W to Week 8), followed by 12 maintenance injections (2 mg of aflibercept Q8W at Weeks 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, and 104).

Primary: Change from Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title	Change from Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
-----------------	--

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥ 74 , 73-55, and ≤ 54 letters), baseline LLD (< 33 and ≥ 33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI

End point type	Primary
----------------	---------

End point timeframe:

From Baseline through Week 48

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	327		
Units: ETDRS Letters				
arithmetic mean (confidence interval 95%)	6.6 (5.3 to 7.8)	6.6 (5.3 to 7.8)		

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 40-48
Statistical analysis description:	
The null hypothesis, $H_0: \mu(\text{faricimab}) - \mu(\text{aflibercept}) \leq -4$ letters; the alternative hypothesis, $H_a: \mu(\text{faricimab}) - \mu(\text{aflibercept}) > -4$ letters. A sample size of approximately 320 participants in each arm provided greater than 90% power to show non-inferiority of faricimab to aflibercept in the change from baseline BCVA averaged over Weeks 40, 44, and 48 in the ITT population, using a non-inferiority margin of 4 letters at the one-sided 0.02485 significance level.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	658
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[1]
Parameter estimate	Adjusted mean difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.7
upper limit	1.8
Variability estimate	Standard error of the mean
Dispersion value	0.91

Notes:

[1] - If the lower bound of a two-sided 95.03% confidence interval (CI) for the difference in adjusted means of the two treatments (faricimab minus aflibercept) is greater than -4 letters (the non-inferiority margin), then faricimab is considered non-inferior to aflibercept.

Secondary: Change from Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

End point title	Change from Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
End point description:	
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥ 74 , 73-55, and ≤ 54 letters), baseline LLD (< 33 and ≥ 33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI	
End point type	Secondary
End point timeframe:	
From Baseline through Week 60	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	327		
Units: ETDRS Letters				
arithmetic mean (confidence interval 95%)	6.6 (5.3 to 7.9)	7.1 (5.8 to 8.4)		

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 52-60
Statistical analysis description:	
The treatment difference in adjusted means of change from baseline BCVA is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	658
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Adjusted mean difference
Point estimate	-0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.4
upper limit	1.3
Variability estimate	Standard error of the mean
Dispersion value	0.93

Secondary: Change from Baseline in BCVA in the Study Eye Over Time

End point title	Change from Baseline in BCVA in the Study Eye Over Time
End point description:	
Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. The Mixed Model of Repeated Measures (MMRM) analysis adjusted for treatment arm, visit, visit-by-treatment arm interaction, baseline BCVA (continuous), baseline BCVA (≥ 74 , 73-55, and ≤ 54 letters), baseline LLD (< 33 and ≥ 33 letters), and region (U.S. and Canada, Asia, and rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. Invalid BCVA values were excluded from analysis. 95% CI is a rounding of 95.03% CI	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	327		
Units: ETDRS Letters				
arithmetic mean (confidence interval 95%)				
Week 4	5.1 (4.2 to 5.9)	4.3 (3.5 to 5.2)		
Week 8	6.0 (5.1 to 6.9)	5.8 (4.9 to 6.8)		
Week 12	7.0 (6.1 to 8.0)	6.4 (5.4 to 7.4)		
Week 16	6.7 (5.6 to 7.7)	6.4 (5.4 to 7.4)		
Week 20	7.0 (5.9 to 8.1)	6.8 (5.7 to 7.9)		
Week 24	7.0 (5.8 to 8.1)	6.5 (5.4 to 7.6)		
Week 28	7.1 (5.9 to 8.2)	6.8 (5.6 to 7.9)		
Week 32	7.2 (6.0 to 8.3)	6.9 (5.7 to 8.0)		
Week 36	6.7 (5.5 to 7.9)	6.8 (5.6 to 8.0)		
Week 40	6.8 (5.5 to 8.1)	6.7 (5.4 to 8.0)		
Week 44	6.5 (5.3 to 7.8)	6.4 (5.2 to 7.7)		
Week 48	6.5 (5.1 to 7.8)	6.4 (5.0 to 7.7)		
Week 52	6.4 (5.1 to 7.7)	6.9 (5.5 to 8.3)		
Week 56	7.1 (5.7 to 8.4)	7.4 (6.0 to 8.7)		
Week 60	6.3 (4.9 to 7.7)	6.9 (5.5 to 8.3)		
Week 64	6.5 (5.1 to 8.0)	6.1 (4.7 to 7.6)		
Week 68	6.2 (4.8 to 7.6)	6.7 (5.3 to 8.1)		
Week 72	6.4 (4.9 to 7.8)	6.2 (4.8 to 7.7)		
Week 76	6.4 (4.9 to 7.9)	6.0 (4.6 to 7.5)		
Week 80	5.9 (4.4 to 7.4)	5.6 (4.1 to 7.2)		
Week 84	5.9 (4.3 to 7.5)	5.8 (4.2 to 7.3)		
Week 88	5.6 (4.1 to 7.1)	5.4 (3.9 to 7.0)		
Week 92	5.7 (4.2 to 7.2)	5.4 (3.9 to 7.0)		
Week 96	5.4 (3.9 to 7.0)	5.5 (3.9 to 7.0)		
Week 100	5.2 (3.6 to 6.8)	4.9 (3.3 to 6.5)		
Week 104	5.0 (3.4 to 6.6)	5.3 (3.7 to 6.9)		
Week 108	5.2 (3.5 to 6.8)	5.4 (3.7 to 7.0)		
Week 112	4.8 (3.2 to 6.5)	4.8 (3.1 to 6.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Gaining Greater Than or Equal to (\geq)15, \geq 10, \geq 5, or \geq 0 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title	Percentage of Participants Gaining Greater Than or Equal to (\geq)15, \geq 10, \geq 5, or \geq 0 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
-----------------	---

End point description:

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of

participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
End point timeframe:	
Baseline, average of Weeks 40, 44, and 48	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	302 ^[2]	291 ^[3]		
Units: Percentage of participants				
number (confidence interval 95%)				
Gaining ≥ 15 Letters	20.2 (15.9 to 24.6)	22.2 (17.7 to 26.8)		
Gaining ≥ 10 Letters	39.2 (34.1 to 44.4)	35.8 (30.6 to 40.9)		
Gaining ≥ 5 Letters	60.5 (55.2 to 65.7)	59.4 (53.9 to 64.9)		
Gaining ≥ 0 Letters	82.2 (77.9 to 86.4)	79.1 (74.5 to 83.6)		

Notes:

[2] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

[3] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

Statistical analyses

Statistical analysis title	Gaining ≥ 15 Letters at Weeks 40-48
Statistical analysis description:	
The treatment difference in CMH weighted percentage of participants gaining ≥ 15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.3
upper limit	4.3

Statistical analysis title	Gaining ≥ 10 Letters at Weeks 40-48
Statistical analysis description:	
The treatment difference in CMH weighted percentage of participants gaining ≥ 10 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept

Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	3.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.9
upper limit	10.7

Statistical analysis title	Gaining ≥ 5 Letters at Weeks 40-48
-----------------------------------	---

Statistical analysis description:

The treatment difference in CMH weighted percentage of participants gaining ≥ 5 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.6
upper limit	8.6

Statistical analysis title	Gaining ≥ 0 Letters at Weeks 40-48
-----------------------------------	---

Statistical analysis description:

The treatment difference in CMH weighted percentage of participants gaining ≥ 0 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	3.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	9.3

Secondary: Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA

in the Study Eye Averaged Over Weeks 52, 56, and 60

End point title	Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
-----------------	---

End point description:

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, average of Weeks 52, 56, and 60

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	289 ^[4]	276 ^[5]		
Units: Percentage of participants				
number (confidence interval 95%)	22.6 (18.1 to 27.1)	23.7 (19.1 to 28.4)		

Notes:

[4] - Participants with at least one non-missing, valid assessment at Weeks 52, 56, or 60.

[5] - Participants with at least one non-missing, valid assessment at Weeks 52, 56, or 60.

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 52-60
----------------------------	-------------------------------------

Statistical analysis description:

The treatment difference in CMH weighted percentage of participants gaining ≥ 15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	565
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	-1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.7
upper limit	5.3

Secondary: Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA in the Study Eye Over Time
End point description:	Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
End point type	Secondary
End point timeframe:	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[6]	327 ^[7]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	10.5 (7.2 to 13.7)	9.5 (6.4 to 12.6)		
Week 8 (n = 327, 322)	13.9 (10.3 to 17.5)	13.5 (10.0 to 17.1)		
Week 12 (n = 326, 317)	17.7 (13.7 to 21.6)	17.2 (13.3 to 21.1)		
Week 16 (n = 321, 315)	17.3 (13.3 to 21.3)	17.7 (13.6 to 21.8)		
Week 20 (n = 320, 309)	20.2 (15.9 to 24.4)	20.2 (15.9 to 24.4)		
Week 24 (n = 295, 288)	19.3 (14.9 to 23.6)	18.9 (14.6 to 23.3)		
Week 28 (n = 292, 271)	23.7 (19.1 to 28.3)	20.8 (16.1 to 25.4)		
Week 32 (n = 287, 288)	22.6 (18.0 to 27.2)	19.5 (15.1 to 23.9)		
Week 36 (n = 293, 283)	22.2 (17.7 to 26.6)	20.6 (16.1 to 25.0)		
Week 40 (n = 286, 288)	23.7 (19.0 to 28.3)	25.4 (20.6 to 30.1)		
Week 44 (n = 285, 273)	21.5 (17.1 to 26.0)	22.4 (17.7 to 27.1)		
Week 48 (n = 282, 277)	22.3 (17.7 to 26.9)	23.1 (18.3 to 27.8)		
Week 52 (n = 283, 273)	22.7 (18.1 to 27.2)	23.4 (18.7 to 28.1)		
Week 56 (n = 283, 273)	25.9 (21.1 to 30.7)	27.0 (22.0 to 32.0)		
Week 60 (n = 278, 273)	22.6 (18.1 to 27.1)	25.8 (20.9 to 30.7)		
Week 64 (n = 276, 266)	25.4 (20.6 to 30.2)	21.2 (16.5 to 25.9)		
Week 68 (n = 276, 266)	24.5 (19.7 to 29.3)	24.9 (20.0 to 29.8)		

Week 72 (n = 276, 261)	22.6 (17.9 to 27.2)	27.1 (22.0 to 32.1)		
Week 76 (n = 268, 267)	22.1 (17.4 to 26.8)	24.9 (20.1 to 29.8)		
Week 80 (n = 275, 264)	22.9 (18.1 to 27.7)	25.8 (20.8 to 30.7)		
Week 84 (n = 279, 254)	23.7 (18.9 to 28.5)	25.6 (20.6 to 30.6)		
Week 88 (n = 276, 253)	24.1 (19.3 to 29.0)	24.4 (19.5 to 29.3)		
Week 92 (n = 273, 253)	22.5 (17.8 to 27.2)	24.8 (19.9 to 29.8)		
Week 96 (n = 266, 247)	25.7 (20.8 to 30.6)	25.5 (20.5 to 30.6)		
Week 100 (n = 272, 254)	24.8 (19.9 to 29.8)	23.1 (18.3 to 28.0)		
Week 104 (n = 263, 249)	22.5 (17.7 to 27.3)	24.6 (19.6 to 29.5)		
Week 108 (n = 267, 247)	21.6 (16.8 to 26.3)	22.3 (17.5 to 27.1)		
Week 112 (n = 267, 254)	25.2 (20.3 to 30.1)	22.5 (17.8 to 27.1)		

Notes:

[6] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[7] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Gaining ≥ 10 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Gaining ≥ 10 Letters from the Baseline BCVA in the Study Eye Over Time
-----------------	--

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[8]	327 ^[9]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	24.2 (19.8 to 28.7)	22.1 (17.7 to 26.5)		
Week 8 (n = 327, 322)	32.4 (27.5 to 37.2)	28.7 (24.1 to 33.4)		
Week 12 (n = 326, 317)	34.2 (29.3 to 39.1)	34.6 (29.5 to 39.7)		
Week 16 (n = 321, 315)	35.3 (30.3 to 40.4)	34.2 (29.2 to 39.3)		
Week 20 (n = 320, 309)	37.8 (32.7 to 42.9)	34.3 (29.2 to 39.4)		
Week 24 (n = 295, 288)	39.2 (33.8 to 44.5)	35.2 (29.9 to 40.5)		
Week 28 (n = 292, 271)	40.5 (35.1 to 45.8)	36.0 (30.5 to 41.4)		
Week 32 (n = 287, 288)	40.5 (35.1 to 46.0)	35.0 (29.7 to 40.3)		
Week 36 (n = 293, 283)	38.9 (33.6 to 44.2)	38.9 (33.5 to 44.3)		
Week 40 (n = 286, 288)	40.9 (35.5 to 46.3)	39.3 (34.0 to 44.7)		
Week 44 (n = 285, 273)	42.3 (36.8 to 47.8)	39.5 (34.1 to 45.0)		
Week 48 (n = 282, 277)	41.0 (35.5 to 46.5)	38.6 (33.2 to 43.9)		
Week 52 (n = 283, 273)	44.2 (38.8 to 49.7)	42.1 (36.6 to 47.6)		
Week 56 (n = 283, 273)	44.2 (38.8 to 49.7)	43.6 (38.1 to 49.2)		
Week 60 (n = 278, 273)	43.1 (37.6 to 48.6)	42.4 (36.8 to 47.9)		
Week 64 (n = 276, 266)	44.0 (38.5 to 49.5)	41.1 (35.4 to 46.8)		
Week 68 (n = 276, 266)	40.1 (34.7 to 45.5)	40.7 (35.3 to 46.2)		
Week 72 (n = 276, 261)	42.0 (36.5 to 47.4)	38.9 (33.4 to 44.3)		
Week 76 (n = 268, 267)	42.2 (36.7 to 47.8)	40.7 (35.1 to 46.2)		
Week 80 (n = 275, 264)	44.2 (38.6 to 49.9)	41.9 (36.2 to 47.6)		
Week 84 (n = 279, 254)	42.7 (37.2 to 48.3)	41.4 (35.6 to 47.2)		
Week 88 (n = 276, 253)	40.3 (34.8 to 45.9)	39.4 (33.7 to 45.1)		
Week 92 (n = 273, 253)	42.1 (36.5 to 47.8)	41.0 (35.3 to 46.7)		
Week 96 (n = 266, 247)	41.1 (35.5 to 46.7)	39.1 (33.3 to 45.0)		
Week 100 (n = 272, 254)	40.2 (34.6 to 45.7)	34.6 (29.0 to 40.1)		
Week 104 (n = 263, 249)	44.0 (38.3 to 49.7)	36.2 (30.5 to 41.9)		
Week 108 (n = 267, 247)	41.7 (36.0 to 47.4)	38.0 (32.2 to 43.8)		

Week 112 (n = 267, 254)	41.3 (35.7 to 47.0)	35.0 (29.6 to 40.5)		
-------------------------	---------------------	---------------------	--	--

Notes:

[8] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[9] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Gaining ≥5 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Gaining ≥5 Letters from the Baseline BCVA in the Study Eye Over Time
-----------------	---

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥74 letters, 73-55 letters, and ≤54 letters), baseline LLD (≥33 letters and <33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[10]	327 ^[11]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	47.8 (42.6 to 53.0)	47.5 (42.2 to 52.8)		
Week 8 (n = 327, 322)	56.8 (51.6 to 62.0)	54.6 (49.3 to 59.8)		
Week 12 (n = 326, 317)	63.9 (58.9 to 68.9)	57.6 (52.3 to 62.9)		
Week 16 (n = 321, 315)	61.7 (56.5 to 66.8)	59.6 (54.3 to 64.9)		
Week 20 (n = 320, 309)	64.1 (59.0 to 69.2)	60.9 (55.6 to 66.3)		
Week 24 (n = 295, 288)	62.2 (56.8 to 67.6)	60.2 (54.7 to 65.7)		
Week 28 (n = 292, 271)	63.6 (58.2 to 68.9)	60.5 (54.8 to 66.2)		
Week 32 (n = 287, 288)	63.3 (58.0 to 68.7)	60.1 (54.6 to 65.6)		
Week 36 (n = 293, 283)	61.4 (56.0 to 66.9)	60.4 (54.9 to 65.9)		

Week 40 (n = 286, 288)	63.5 (58.1 to 68.9)	60.9 (55.5 to 66.4)		
Week 44 (n = 285, 273)	60.1 (54.6 to 65.6)	62.3 (56.7 to 67.8)		
Week 48 (n = 282, 277)	60.0 (54.5 to 65.6)	63.5 (57.9 to 69.1)		
Week 52 (n = 283, 273)	63.5 (58.1 to 69.0)	67.2 (61.7 to 72.6)		
Week 56 (n = 283, 273)	64.1 (58.7 to 69.5)	66.5 (61.0 to 72.0)		
Week 60 (n = 278, 273)	61.6 (56.1 to 67.2)	65.5 (59.9 to 71.0)		
Week 64 (n = 276, 266)	65.2 (59.8 to 70.6)	63.1 (57.5 to 68.8)		
Week 68 (n = 276, 266)	63.0 (57.4 to 68.5)	64.0 (58.5 to 69.6)		
Week 72 (n = 276, 261)	64.1 (58.6 to 69.6)	66.6 (60.9 to 72.2)		
Week 76 (n = 268, 267)	63.9 (58.2 to 69.6)	58.7 (53.0 to 64.4)		
Week 80 (n = 275, 264)	63.3 (57.7 to 68.9)	62.3 (56.6 to 67.9)		
Week 84 (n = 279, 254)	61.6 (56.1 to 67.2)	64.3 (58.6 to 70.1)		
Week 88 (n = 276, 253)	62.6 (57.1 to 68.1)	60.7 (54.9 to 66.5)		
Week 92 (n = 273, 253)	62.7 (57.1 to 68.3)	58.3 (52.6 to 64.0)		
Week 96 (n = 266, 247)	61.3 (55.6 to 67.0)	61.0 (55.1 to 67.0)		
Week 100 (n = 272, 254)	61.7 (56.1 to 67.3)	56.9 (50.9 to 62.9)		
Week 104 (n = 263, 249)	60.3 (54.6 to 66.0)	59.3 (53.3 to 65.3)		
Week 108 (n = 267, 247)	62.4 (56.8 to 68.0)	58.0 (51.8 to 64.1)		
Week 112 (n = 267, 254)	59.9 (54.2 to 65.6)	59.4 (53.4 to 65.3)		

Notes:

[10] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[11] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Gaining ≥ 0 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Gaining ≥ 0 Letters from the Baseline BCVA in the Study Eye Over Time
-----------------	---

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[12]	327 ^[13]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	80.5 (76.3 to 84.7)	74.2 (69.5 to 78.9)		
Week 8 (n = 327, 322)	82.3 (78.3 to 86.3)	80.3 (76.0 to 84.5)		
Week 12 (n = 326, 317)	84.1 (80.3 to 88.0)	81.0 (76.8 to 85.1)		
Week 16 (n = 321, 315)	82.6 (78.5 to 86.6)	83.0 (78.9 to 87.0)		
Week 20 (n = 320, 309)	84.8 (80.9 to 88.6)	83.1 (79.1 to 87.2)		
Week 24 (n = 295, 288)	82.8 (78.6 to 86.9)	82.0 (77.6 to 86.4)		
Week 28 (n = 292, 271)	82.7 (78.5 to 86.8)	83.0 (78.7 to 87.4)		
Week 32 (n = 287, 288)	80.3 (75.9 to 84.7)	82.2 (77.8 to 86.5)		
Week 36 (n = 293, 283)	81.2 (76.8 to 85.6)	76.5 (71.7 to 81.3)		
Week 40 (n = 286, 288)	82.0 (77.6 to 86.3)	77.6 (72.9 to 82.3)		
Week 44 (n = 285, 273)	84.0 (79.8 to 88.2)	78.6 (73.9 to 83.2)		
Week 48 (n = 282, 277)	82.7 (78.3 to 87.1)	78.9 (74.1 to 83.6)		
Week 52 (n = 283, 273)	79.4 (74.8 to 84.0)	84.7 (80.5 to 88.9)		
Week 56 (n = 283, 273)	80.7 (76.1 to 85.2)	82.6 (78.2 to 87.0)		
Week 60 (n = 278, 273)	78.9 (74.2 to 83.6)	81.5 (77.0 to 86.0)		
Week 64 (n = 276, 266)	81.3 (76.8 to 85.8)	81.1 (76.5 to 85.7)		
Week 68 (n = 276, 266)	80.5 (76.0 to 85.1)	80.4 (75.8 to 85.0)		
Week 72 (n = 276, 261)	79.5 (74.8 to 84.1)	78.8 (74.0 to 83.6)		
Week 76 (n = 268, 267)	81.0 (76.4 to 85.6)	79.8 (75.2 to 84.5)		
Week 80 (n = 275, 264)	80.0 (75.3 to 84.7)	76.0 (71.0 to 81.1)		
Week 84 (n = 279, 254)	78.7 (73.9 to 83.5)	81.0 (76.3 to 85.7)		
Week 88 (n = 276, 253)	78.7 (73.9 to 83.5)	80.6 (75.9 to 85.4)		
Week 92 (n = 273, 253)	81.3 (76.7 to 85.8)	76.3 (71.2 to 81.4)		

Week 96 (n = 266, 247)	76.3 (71.3 to 81.3)	77.5 (72.5 to 82.6)		
Week 100 (n = 272, 254)	75.7 (70.8 to 80.7)	74.8 (69.6 to 80.0)		
Week 104 (n = 263, 249)	76.6 (71.6 to 81.6)	79.0 (74.0 to 84.0)		
Week 108 (n = 267, 247)	78.8 (74.0 to 83.6)	76.9 (71.7 to 82.1)		
Week 112 (n = 267, 254)	74.6 (69.5 to 79.8)	77.4 (72.3 to 82.5)		

Notes:

[12] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[13] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Avoiding a Loss of ≥ 15 , ≥ 10 , or ≥ 5 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title	Percentage of Participants Avoiding a Loss of ≥ 15 , ≥ 10 , or ≥ 5 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48
-----------------	--

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, average of Weeks 40, 44, and 48

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	302 ^[14]	291 ^[15]		
Units: Percentage of participants				
number (confidence interval 95%)				
Avoiding a Loss of ≥ 15 Letters	95.8 (93.6 to 98.0)	97.3 (95.5 to 99.1)		
Avoiding a Loss of ≥ 10 Letters	93.8 (91.1 to 96.4)	94.6 (92.2 to 97.1)		
Avoiding a Loss of ≥ 5 Letters	91.2 (88.0 to 94.3)	88.5 (85.0 to 92.0)		

Notes:

[14] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

[15] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

Statistical analyses

Statistical analysis title	Avoiding a Loss of ≥ 15 Letters at Weeks 40-48
Statistical analysis description:	
The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥ 15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	-1.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.4
upper limit	1.3

Statistical analysis title	Avoiding a Loss of ≥ 5 Letters at Weeks 40-48
Statistical analysis description:	
The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥ 5 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	7.3

Statistical analysis title	Avoiding a Loss of ≥ 10 Letters at Weeks 40-48
Statistical analysis description:	
The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥ 10 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	-0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.5
upper limit	2.8

Secondary: Percentage of Participants Avoiding a Loss of ≥ 15 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60

End point title	Percentage of Participants Avoiding a Loss of ≥ 15 Letters from the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60
-----------------	--

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was then used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, average of Weeks 52, 56, and 60

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	289 ^[16]	276 ^[17]		
Units: Percentage of participants				
number (confidence interval 95%)	96.5 (94.4 to 98.6)	96.1 (94.0 to 98.3)		

Notes:

[16] - Participants with at least one non-missing, valid assessment at Weeks 52, 56, or 60.

[17] - Participants with at least one non-missing, valid assessment at Weeks 52, 56, or 60.

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 52-60
-----------------------------------	-------------------------------------

Statistical analysis description:

The treatment difference in CMH weighted percentage of participants avoiding a loss of ≥ 15 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	565
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.6
upper limit	3.3

Secondary: Percentage of Participants Avoiding a Loss of ≥ 15 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Avoiding a Loss of ≥ 15 Letters from the Baseline BCVA in the Study Eye Over Time
-----------------	---

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[18]	327 ^[19]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	99.4 (98.6 to 100.0)	98.1 (96.7 to 99.6)		
Week 8 (n = 327, 322)	98.5 (97.3 to 99.8)	97.8 (96.3 to 99.4)		
Week 12 (n = 326, 317)	98.5 (97.3 to 99.8)	98.1 (96.7 to 99.6)		
Week 16 (n = 321, 315)	97.6 (96.0 to 99.2)	98.4 (97.0 to 99.8)		
Week 20 (n = 320, 309)	97.3 (95.5 to 99.0)	98.4 (97.0 to 99.7)		
Week 24 (n = 295, 288)	96.6 (94.6 to 98.6)	97.2 (95.4 to 99.1)		
Week 28 (n = 292, 271)	97.0 (95.1 to 98.9)	97.8 (96.2 to 99.5)		
Week 32 (n = 287, 288)	97.0 (95.1 to 98.9)	96.9 (95.0 to 98.9)		
Week 36 (n = 293, 283)	97.0 (95.2 to 98.9)	96.5 (94.5 to 98.6)		
Week 40 (n = 286, 288)	96.2 (94.1 to 98.4)	97.6 (95.9 to 99.3)		
Week 44 (n = 285, 273)	95.9 (93.6 to 98.1)	96.4 (94.3 to 98.5)		
Week 48 (n = 282, 277)	95.8 (93.5 to 98.0)	96.9 (95.0 to 98.8)		
Week 52 (n = 283, 273)	94.9 (92.5 to 97.4)	96.8 (94.8 to 98.8)		
Week 56 (n = 283, 273)	96.1 (93.9 to 98.3)	96.8 (94.8 to 98.8)		

Week 60 (n = 278, 273)	95.0 (92.5 to 97.5)	96.1 (94.0 to 98.3)		
Week 64 (n = 276, 266)	96.4 (94.3 to 98.5)	94.9 (92.3 to 97.4)		
Week 68 (n = 276, 266)	94.7 (92.1 to 97.2)	96.0 (93.7 to 98.3)		
Week 72 (n = 276, 261)	94.5 (91.9 to 97.2)	95.4 (92.9 to 97.9)		
Week 76 (n = 268, 267)	94.9 (92.3 to 97.4)	93.7 (90.9 to 96.6)		
Week 80 (n = 275, 264)	93.9 (91.1 to 96.6)	93.3 (90.4 to 96.3)		
Week 84 (n = 279, 254)	92.5 (89.5 to 95.5)	93.8 (90.9 to 96.7)		
Week 88 (n = 276, 253)	94.1 (91.4 to 96.7)	94.3 (91.5 to 97.0)		
Week 92 (n = 273, 253)	93.0 (90.2 to 95.9)	94.6 (92.0 to 97.2)		
Week 96 (n = 266, 247)	92.6 (89.6 to 95.6)	95.0 (92.5 to 97.6)		
Week 100 (n = 272, 254)	92.5 (89.5 to 95.5)	93.9 (91.1 to 96.7)		
Week 104 (n = 263, 249)	92.9 (90.0 to 95.9)	94.0 (91.0 to 96.9)		
Week 108 (n = 267, 247)	92.3 (89.2 to 95.3)	93.3 (90.3 to 96.3)		
Week 112 (n = 267, 254)	91.8 (88.7 to 95.0)	93.0 (89.9 to 96.1)		

Notes:

[18] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[19] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Avoiding a Loss of ≥ 10 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Avoiding a Loss of ≥ 10 Letters from the Baseline BCVA in the Study Eye Over Time
-----------------	---

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[20]	327 ^[21]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	98.5 (97.2 to 99.8)	96.2 (94.1 to 98.3)		
Week 8 (n = 327, 322)	97.0 (95.3 to 98.7)	96.9 (95.0 to 98.7)		
Week 12 (n = 326, 317)	97.0 (95.2 to 98.8)	96.8 (94.9 to 98.7)		
Week 16 (n = 321, 315)	96.6 (94.7 to 98.5)	96.8 (94.9 to 98.7)		
Week 20 (n = 320, 309)	95.2 (92.9 to 97.4)	96.1 (94.0 to 98.2)		
Week 24 (n = 295, 288)	95.2 (92.9 to 97.6)	95.5 (93.2 to 97.8)		
Week 28 (n = 292, 271)	95.0 (92.6 to 97.4)	95.2 (92.7 to 97.7)		
Week 32 (n = 287, 288)	94.6 (92.1 to 97.1)	95.9 (93.7 to 98.1)		
Week 36 (n = 293, 283)	95.3 (93.0 to 97.7)	94.4 (91.8 to 97.0)		
Week 40 (n = 286, 288)	93.8 (91.1 to 96.5)	94.6 (92.2 to 97.1)		
Week 44 (n = 285, 273)	94.1 (91.4 to 96.8)	92.1 (89.1 to 95.1)		
Week 48 (n = 282, 277)	92.2 (89.2 to 95.3)	94.8 (92.3 to 97.3)		
Week 52 (n = 283, 273)	91.4 (88.2 to 94.6)	93.8 (91.1 to 96.6)		
Week 56 (n = 283, 273)	93.3 (90.5 to 96.2)	95.0 (92.5 to 97.5)		
Week 60 (n = 278, 273)	91.4 (88.2 to 94.6)	93.2 (90.4 to 96.1)		
Week 64 (n = 276, 266)	93.5 (90.7 to 96.4)	92.3 (89.3 to 95.4)		
Week 68 (n = 276, 266)	91.9 (88.8 to 95.0)	92.9 (89.9 to 96.0)		
Week 72 (n = 276, 261)	92.4 (89.3 to 95.5)	91.6 (88.3 to 94.9)		
Week 76 (n = 268, 267)	93.1 (90.2 to 96.0)	90.1 (86.5 to 93.6)		
Week 80 (n = 275, 264)	92.1 (89.0 to 95.2)	89.9 (86.3 to 93.5)		
Week 84 (n = 279, 254)	90.3 (86.9 to 93.7)	91.8 (88.4 to 95.1)		
Week 88 (n = 276, 253)	90.8 (87.5 to 94.1)	92.3 (89.1 to 95.4)		
Week 92 (n = 273, 253)	90.7 (87.4 to 94.1)	91.0 (87.6 to 94.5)		
Week 96 (n = 266, 247)	90.4 (87.0 to 93.8)	92.6 (89.4 to 95.8)		
Week 100 (n = 272, 254)	90.7 (87.4 to 94.0)	91.6 (88.3 to 94.9)		
Week 104 (n = 263, 249)	89.0 (85.4 to 92.7)	92.2 (88.9 to 95.4)		
Week 108 (n = 267, 247)	88.5 (84.8 to 92.3)	91.2 (87.7 to 94.7)		

Week 112 (n = 267, 254)	88.5 (84.7 to 92.2)	89.5 (85.8 to 93.2)		
-------------------------	---------------------	---------------------	--	--

Notes:

[20] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[21] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Avoiding a Loss of ≥ 5 Letters from the Baseline BCVA in the Study Eye Over Time

End point title	Percentage of Participants Avoiding a Loss of ≥ 5 Letters from the Baseline BCVA in the Study Eye Over Time
End point description:	Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The weighted percentage of participants avoiding a loss of letters in BCVA from baseline was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.
End point type	Secondary
End point timeframe:	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[22]	327 ^[23]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	93.0 (90.4 to 95.6)	91.8 (88.9 to 94.7)		
Week 8 (n = 327, 322)	93.1 (90.4 to 95.7)	94.1 (91.5 to 96.6)		
Week 12 (n = 326, 317)	93.3 (90.7 to 95.9)	91.8 (88.8 to 94.7)		
Week 16 (n = 321, 315)	91.7 (88.7 to 94.6)	90.8 (87.7 to 94.0)		
Week 20 (n = 320, 309)	92.0 (89.1 to 94.9)	92.9 (90.0 to 95.7)		
Week 24 (n = 295, 288)	90.6 (87.4 to 93.9)	91.7 (88.6 to 94.8)		
Week 28 (n = 292, 271)	91.0 (87.9 to 94.1)	90.2 (86.7 to 93.7)		
Week 32 (n = 287, 288)	89.9 (86.5 to 93.2)	91.0 (87.7 to 94.3)		
Week 36 (n = 293, 283)	90.7 (87.5 to 94.0)	87.4 (83.6 to 91.2)		
Week 40 (n = 286, 288)	91.7 (88.6 to 94.9)	88.1 (84.5 to 91.7)		

Week 44 (n = 285, 273)	90.9 (87.7 to 94.2)	88.8 (85.3 to 92.3)		
Week 48 (n = 282, 277)	89.4 (85.9 to 93.0)	88.6 (85.0 to 92.2)		
Week 52 (n = 283, 273)	88.9 (85.3 to 92.5)	91.7 (88.6 to 94.8)		
Week 56 (n = 283, 273)	89.5 (86.0 to 93.0)	88.8 (85.2 to 92.5)		
Week 60 (n = 278, 273)	86.7 (82.9 to 90.6)	88.8 (85.2 to 92.4)		
Week 64 (n = 276, 266)	87.8 (84.1 to 91.6)	86.0 (82.0 to 90.1)		
Week 68 (n = 276, 266)	88.2 (84.5 to 91.9)	87.1 (83.2 to 91.0)		
Week 72 (n = 276, 261)	87.0 (83.1 to 90.9)	87.3 (83.4 to 91.2)		
Week 76 (n = 268, 267)	87.1 (83.2 to 91.1)	85.4 (81.2 to 89.5)		
Week 80 (n = 275, 264)	87.3 (83.5 to 91.2)	82.8 (78.3 to 87.3)		
Week 84 (n = 279, 254)	84.1 (79.9 to 88.4)	87.1 (83.1 to 91.2)		
Week 88 (n = 276, 253)	87.5 (83.7 to 91.3)	86.6 (82.5 to 90.6)		
Week 92 (n = 273, 253)	87.0 (83.1 to 90.9)	87.2 (83.2 to 91.2)		
Week 96 (n = 266, 247)	82.7 (78.4 to 87.1)	86.2 (82.1 to 90.4)		
Week 100 (n = 272, 254)	85.9 (81.9 to 89.8)	84.2 (79.9 to 88.5)		
Week 104 (n = 263, 249)	83.5 (79.1 to 87.8)	85.4 (81.1 to 89.7)		
Week 108 (n = 267, 247)	84.1 (79.9 to 88.4)	83.9 (79.4 to 88.5)		
Week 112 (n = 267, 254)	82.2 (77.7 to 86.7)	84.4 (80.0 to 88.8)		

Notes:

[22] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[23] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥ 84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title	Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥ 84 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
-----------------	--

End point description:

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
End point timeframe:	
Baseline, average of Weeks 40, 44, and 48	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	302 ^[24]	291 ^[25]		
Units: Percentage of participants				
number (confidence interval 95%)	24.5 (19.8 to 29.2)	26.2 (21.2 to 31.1)		

Notes:

[24] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

[25] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 40-48
Statistical analysis description:	
The treatment difference in CMH weighted percentage of participants gaining ≥ 15 letters or achieving BCVA ≥ 84 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.	
Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.5
upper limit	5.1

Secondary: Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥ 84 Letters) in the Study Eye Over Time

End point title	Percentage of Participants Gaining ≥ 15 Letters from the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or Better (BCVA ≥ 84 Letters) in the Study Eye Over Time
-----------------	---

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[26]	327 ^[27]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	11.3 (7.9 to 14.6)	12.4 (8.9 to 15.9)		
Week 8 (n = 327, 322)	16.5 (12.5 to 20.4)	16.1 (12.2 to 20.0)		
Week 12 (n = 326, 317)	22.0 (17.7 to 26.4)	21.1 (16.7 to 25.4)		
Week 16 (n = 321, 315)	21.7 (17.4 to 26.1)	20.7 (16.2 to 25.1)		
Week 20 (n = 320, 309)	24.9 (20.2 to 29.5)	24.9 (20.2 to 29.6)		
Week 24 (n = 295, 288)	23.6 (18.9 to 28.3)	23.7 (18.9 to 28.6)		
Week 28 (n = 292, 271)	27.7 (22.7 to 32.7)	26.9 (21.8 to 32.1)		
Week 32 (n = 287, 288)	28.7 (23.6 to 33.8)	23.2 (18.4 to 27.9)		
Week 36 (n = 293, 283)	25.9 (21.1 to 30.7)	24.6 (19.7 to 29.5)		
Week 40 (n = 286, 288)	27.9 (22.9 to 32.9)	31.1 (25.9 to 36.4)		
Week 44 (n = 285, 273)	27.2 (22.2 to 32.1)	28.1 (22.8 to 33.3)		
Week 48 (n = 282, 277)	27.3 (22.3 to 32.4)	28.3 (23.1 to 33.6)		
Week 52 (n = 283, 273)	29.2 (24.1 to 34.3)	28.3 (23.1 to 33.5)		
Week 56 (n = 283, 273)	32.0 (26.7 to 37.2)	31.5 (26.1 to 36.9)		
Week 60 (n = 278, 273)	27.5 (22.5 to 32.5)	31.4 (26.0 to 36.8)		
Week 64 (n = 276, 266)	30.1 (25.0 to 35.3)	27.1 (21.9 to 32.3)		
Week 68 (n = 276, 266)	28.3 (23.1 to 33.4)	30.0 (24.6 to 35.3)		
Week 72 (n = 276, 261)	26.4 (21.4 to 31.4)	31.5 (26.0 to 36.9)		
Week 76 (n = 268, 267)	27.4 (22.2 to 32.5)	29.2 (23.9 to 34.4)		
Week 80 (n = 275, 264)	28.7 (23.4 to 34.0)	31.2 (25.7 to 36.6)		
Week 84 (n = 279, 254)	28.0 (22.8 to 33.1)	30.1 (24.6 to 35.5)		
Week 88 (n = 276, 253)	29.1 (23.8 to 34.4)	28.4 (23.2 to 33.6)		
Week 92 (n = 273, 253)	27.0 (21.8 to 32.1)	29.0 (23.6 to 34.3)		

Week 96 (n = 266, 247)	30.7 (25.3 to 36.0)	31.1 (25.5 to 36.6)		
Week 100 (n = 272, 254)	28.6 (23.3 to 33.9)	27.2 (22.0 to 32.5)		
Week 104 (n = 263, 249)	27.2 (22.0 to 32.4)	30.2 (24.8 to 35.6)		
Week 108 (n = 267, 247)	26.3 (21.1 to 31.4)	27.0 (21.7 to 32.4)		
Week 112 (n = 267, 254)	29.4 (24.1 to 34.7)	26.5 (21.4 to 31.6)		

Notes:

[26] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[27] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better (BCVA \geq 69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title	Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better (BCVA \geq 69 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
-----------------	---

End point description:

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted estimates of the percentage of participants were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (<69 letters vs. \geq 69 letters), baseline LLD (\geq 33 letters and <33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, average of Weeks 40, 44, and 48

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	302 ^[28]	291 ^[29]		
Units: Percentage of participants				
number (confidence interval 95%)	55.2 (50.1 to 60.2)	49.4 (44.4 to 54.4)		

Notes:

[28] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

[29] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 40-48
----------------------------	-------------------------------------

Statistical analysis description:

The treatment difference in CMH weighted percentage of participants achieving BCVA \geq 69 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	5.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	12.9

Secondary: Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better (BCVA \geq 69 Letters) in the Study Eye Over Time

End point title	Percentage of Participants with BCVA Snellen Equivalent of 20/40 or Better (BCVA \geq 69 Letters) in the Study Eye Over Time
-----------------	--

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (<69 letters vs. \geq 69 letters), baseline LLD (\geq 33 letters and <33 letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[30]	327 ^[31]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	45.7 (41.1 to 50.2)	40.1 (35.8 to 44.5)		
Week 8 (n = 327, 322)	50.5 (45.8 to 55.1)	45.2 (40.7 to 49.7)		
Week 12 (n = 326, 317)	53.5 (48.8 to 58.3)	48.5 (43.8 to 53.3)		
Week 16 (n = 321, 315)	56.1 (51.2 to 60.9)	47.4 (42.8 to 52.1)		
Week 20 (n = 320, 309)	57.5 (52.6 to 62.4)	51.1 (46.3 to 55.9)		
Week 24 (n = 295, 288)	57.4 (52.4 to 62.4)	47.8 (42.9 to 52.8)		

Week 28 (n = 292, 271)	55.2 (50.0 to 60.4)	48.2 (43.2 to 53.2)		
Week 32 (n = 287, 288)	55.9 (50.8 to 61.1)	49.8 (45.0 to 54.6)		
Week 36 (n = 293, 283)	56.0 (50.9 to 61.0)	47.4 (42.2 to 52.6)		
Week 40 (n = 286, 288)	54.7 (49.5 to 59.9)	52.7 (47.5 to 57.9)		
Week 44 (n = 285, 273)	56.3 (51.4 to 61.3)	52.5 (47.3 to 57.7)		
Week 48 (n = 282, 277)	55.0 (49.8 to 60.2)	52.3 (47.1 to 57.5)		
Week 52 (n = 283, 273)	55.9 (50.6 to 61.1)	55.6 (50.4 to 60.9)		
Week 56 (n = 283, 273)	57.1 (51.8 to 62.3)	52.9 (47.7 to 58.2)		
Week 60 (n = 278, 273)	53.0 (47.6 to 58.3)	53.6 (48.3 to 58.9)		
Week 64 (n = 276, 266)	58.8 (53.5 to 64.2)	52.9 (47.5 to 58.3)		
Week 68 (n = 276, 266)	57.0 (51.7 to 62.4)	55.5 (50.0 to 60.9)		
Week 72 (n = 276, 261)	58.1 (52.7 to 63.4)	53.3 (48.0 to 58.6)		
Week 76 (n = 268, 267)	58.0 (52.6 to 63.4)	54.0 (48.6 to 59.3)		
Week 80 (n = 275, 264)	57.3 (52.0 to 62.6)	51.9 (46.5 to 57.4)		
Week 84 (n = 279, 254)	58.4 (53.1 to 63.7)	56.9 (51.5 to 62.4)		
Week 88 (n = 276, 253)	57.2 (51.9 to 62.6)	51.1 (45.6 to 56.5)		
Week 92 (n = 273, 253)	56.1 (50.8 to 61.4)	54.9 (49.5 to 60.3)		
Week 96 (n = 266, 247)	55.5 (49.9 to 61.0)	53.9 (48.4 to 59.4)		
Week 100 (n = 272, 254)	55.1 (49.5 to 60.7)	51.7 (46.2 to 57.2)		
Week 104 (n = 263, 249)	55.1 (49.4 to 60.7)	52.8 (47.3 to 58.2)		
Week 108 (n = 267, 247)	54.8 (49.1 to 60.4)	51.0 (45.5 to 56.5)		
Week 112 (n = 267, 254)	55.7 (50.2 to 61.1)	51.0 (45.6 to 56.4)		

Notes:

[30] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[31] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse (BCVA \leq 38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title	Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse (BCVA \leq 38 Letters) in the Study Eye Averaged Over Weeks 40, 44, and 48
-----------------	---

End point description:

BCVA was measured on the ETDRS chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity. For each participant, an average BCVA value was calculated across the three visits, and this

averaged value was used to determine if the endpoint was met. The results were summarized as the percentage of participants per treatment arm who met the endpoint. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Treatment policy strategy and hypothetical strategy were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
End point timeframe:	
Baseline, average of Weeks 40, 44, and 48	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	302 ^[32]	291 ^[33]		
Units: Percentage of participants				
number (confidence interval 95%)	7.9 (5.0 to 10.8)	7.5 (4.7 to 10.3)		

Notes:

[32] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

[33] - Participants with at least one non-missing, valid assessment at Weeks 40, 44, or 48.

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 40-48
-----------------------------------	-------------------------------------

Statistical analysis description:

The treatment difference in CMH weighted percentage of participants with BCVA ≤ 38 letters is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	593
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Difference in CMH Weighted Percentage
Point estimate	0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.6
upper limit	4.4

Secondary: Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤ 38 Letters) in the Study Eye Over Time

End point title	Percentage of Participants with BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤ 38 Letters) in the Study Eye Over Time
-----------------	--

End point description:

Best Corrected Visual Acuity (BCVA) was measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters. The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The weighted percentage of participants was based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33

letters), and region (U.S. and Canada vs. rest of the world; Asia and rest of the world were combined). Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. Invalid BCVA values were excluded from analysis. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[34]	327 ^[35]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 328, 323)	6.8 (4.3 to 9.4)	6.1 (3.7 to 8.5)		
Week 8 (n = 327, 322)	7.4 (4.8 to 10.1)	6.2 (3.7 to 8.6)		
Week 12 (n = 326, 317)	7.6 (5.0 to 10.2)	5.9 (3.5 to 8.3)		
Week 16 (n = 321, 315)	9.5 (6.6 to 12.5)	5.3 (3.0 to 7.6)		
Week 20 (n = 320, 309)	9.3 (6.4 to 12.3)	5.7 (3.3 to 8.1)		
Week 24 (n = 295, 288)	8.1 (5.2 to 11.1)	6.3 (3.7 to 8.9)		
Week 28 (n = 292, 271)	7.4 (4.6 to 10.3)	6.4 (3.7 to 9.1)		
Week 32 (n = 287, 288)	8.1 (5.1 to 11.0)	6.6 (4.0 to 9.2)		
Week 36 (n = 293, 283)	7.8 (4.9 to 10.6)	6.8 (4.1 to 9.5)		
Week 40 (n = 286, 288)	8.3 (5.3 to 11.3)	7.6 (4.8 to 10.3)		
Week 44 (n = 285, 273)	7.9 (4.9 to 10.9)	6.8 (4.0 to 9.5)		
Week 48 (n = 282, 277)	9.7 (6.5 to 12.9)	6.3 (3.6 to 9.0)		
Week 52 (n = 283, 273)	9.1 (6.0 to 12.2)	6.5 (3.7 to 9.2)		
Week 56 (n = 283, 273)	8.1 (5.1 to 11.1)	6.3 (3.6 to 9.0)		
Week 60 (n = 278, 273)	8.2 (5.2 to 11.3)	7.3 (4.5 to 10.2)		
Week 64 (n = 276, 266)	7.1 (4.2 to 10.1)	7.2 (4.3 to 10.1)		
Week 68 (n = 276, 266)	8.8 (5.6 to 12.0)	6.8 (4.0 to 9.6)		
Week 72 (n = 276, 261)	8.4 (5.2 to 11.6)	6.2 (3.4 to 8.9)		
Week 76 (n = 268, 267)	9.5 (6.2 to 12.9)	7.4 (4.5 to 10.3)		
Week 80 (n = 275, 264)	9.8 (6.5 to 13.1)	8.4 (5.3 to 11.5)		
Week 84 (n = 279, 254)	9.3 (6.0 to 12.6)	7.2 (4.2 to 10.1)		

Week 88 (n = 276, 253)	8.4 (5.2 to 11.6)	7.5 (4.5 to 10.4)		
Week 92 (n = 273, 253)	8.9 (5.6 to 12.2)	9.0 (5.8 to 12.2)		
Week 96 (n = 266, 247)	10.4 (6.8 to 13.9)	9.7 (6.5 to 13.0)		
Week 100 (n = 272, 254)	10.3 (6.8 to 13.8)	10.9 (7.5 to 14.4)		
Week 104 (n = 263, 249)	9.2 (5.8 to 12.6)	9.8 (6.4 to 13.1)		
Week 108 (n = 267, 247)	9.5 (6.0 to 12.9)	10.0 (6.5 to 13.4)		
Week 112 (n = 267, 254)	9.0 (5.7 to 12.4)	10.6 (7.1 to 14.0)		

Notes:

[34] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[35] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48

End point title	Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 48 ^[36]
-----------------	---

End point description:

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 48. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 48

Notes:

[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only applicable to participants who were randomized to Arm A: Faricimab.

End point values	Arm A: Faricimab			
Subject group type	Reporting group			
Number of subjects analysed	316			
Units: Percentage of participants				
number (confidence interval 95%)				
Once Every 8 Weeks	22.2 (17.6 to 26.7)			
Once Every 12 Weeks	32.9 (27.7 to 38.1)			
Once Every 16 Weeks	44.9 (39.4 to 50.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60

End point title	Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 60 ^[37]
-----------------	---

End point description:

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 60. The treatment interval at a given visit is defined as the treatment interval decision followed at that visit. The 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 60

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only applicable to participants who were randomized to Arm A: Faricimab.

End point values	Arm A: Faricimab			
Subject group type	Reporting group			
Number of subjects analysed	305			
Units: Percentage of participants				
number (confidence interval 95%)				
Once Every 8 Weeks	21.6 (17.0 to 26.3)			
Once Every 12 Weeks	32.8 (27.5 to 38.1)			
Once Every 16 Weeks	45.6 (40.0 to 51.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112

End point title	Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among Those Completing Week 112 ^[38]
-----------------	--

End point description:

Percentages are based on the number of participants randomized to the faricimab arm who have not discontinued the study at Week 112. Treatment interval at a given visit is defined as the treatment interval decision followed at that visit. Treatment interval at Week 112 is calculated using data recorded at Week 108. The 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 108 and 112

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only applicable to participants who were randomized to Arm A: Faricimab.

End point values	Arm A: Faricimab			
Subject group type	Reporting group			
Number of subjects analysed	287			
Units: Percentage of participants				
number (confidence interval 95%)				
Once Every 8 Weeks	18.8 (14.3 to 23.3)			
Once Every 12 Weeks	14.3 (10.2 to 18.3)			
Once Every 16 Weeks	66.9 (61.4 to 72.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Study Drug Injections Received in the Study Eye Through Week 48

End point title	Number of Study Drug Injections Received in the Study Eye Through Week 48
-----------------	---

End point description:

This analysis was performed on the safety-evaluable population, which included all participants who received at least one dose of active study drug (faricimab or aflibercept) in the study eye.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline through Week 48

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	326		
Units: Injections				
median (full range (min-max))	6.0 (1 to 8)	8.0 (1 to 8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Study Drug Injections Received in the Study Eye Through Week 60

End point title	Number of Study Drug Injections Received in the Study Eye Through Week 60
-----------------	---

End point description:

This analysis was performed on the safety-evaluable population, which included all participants who received at least one dose of active study drug (faricimab or aflibercept) in the study eye.

End point type Secondary

End point timeframe:

From Baseline through Week 60

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	326		
Units: Injections				
median (full range (min-max))	7.0 (1 to 10)	9.0 (1 to 9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Study Drug Injections Received in the Study Eye Through Week 108

End point title Number of Study Drug Injections Received in the Study Eye Through Week 108

End point description:

This analysis was performed on the safety-evaluable population, which included all participants who received at least one dose of active study drug (faricimab or aflibercept) in the study eye.

End point type Secondary

End point timeframe:

From Baseline through Week 108

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	326		
Units: Injections				
median (full range (min-max))	10.0 (1 to 16)	15.0 (1 to 15)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 40, 44, and 48

End point title Change from Baseline in Central Subfield Thickness in the

End point description:

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (< 33 letters and ≥ 33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline through Week 48

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	327		
Units: microns				
arithmetic mean (confidence interval 95%)	-137.1 (-143.1 to -131.2)	-130.8 (-136.8 to -124.8)		

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 40-48
----------------------------	-------------------------------------

Statistical analysis description:

The treatment difference in adjusted means of change from baseline CST is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	658
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Adjusted mean difference
Point estimate	-6.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.8
upper limit	2.1
Variability estimate	Standard error of the mean
Dispersion value	4.3

Secondary: Change from Baseline in Central Subfield Thickness in the Study Eye Averaged Over Weeks 52, 56, and 60

End point title	Change from Baseline in Central Subfield Thickness in the
-----------------	---

End point description:

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (< 33 letters and ≥ 33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline through Week 60

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	327		
Units: microns				
arithmetic mean (confidence interval 95%)	-135.7 (-141.2 to -130.1)	-137.0 (-142.7 to -131.3)		

Statistical analyses

Statistical analysis title	Treatment Difference at Weeks 52-60
----------------------------	-------------------------------------

Statistical analysis description:

The treatment difference in adjusted means of change from baseline CST is the calculated difference of Arm A: Faricimab and Arm B: Aflibercept. MMRM adjustments are listed in the outcome measure description.

Comparison groups	Arm A: Faricimab v Arm B: Aflibercept
Number of subjects included in analysis	658
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Adjusted mean difference
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.6
upper limit	9.3
Variability estimate	Standard error of the mean
Dispersion value	4.05

Secondary: Change from Baseline in Central Subfield Thickness in the Study Eye Over Time

End point title	Change from Baseline in Central Subfield Thickness in the
-----------------	---

End point description:

Central subfield thickness (CST) was defined as the distance between the internal limiting membrane (ILM) and the retinal pigment epithelium (RPE) using optical coherence tomography (OCT), as assessed by the central reading center. For the Mixed Model of Repeated Measures (MMRM) analysis, the model adjusted for treatment group, visit, visit-by-treatment group interaction, baseline CST (continuous), baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (< 33 letters and ≥ 33 letters), and region (U.S. and Canada, Asia, and the rest of the world). An unstructured covariance structure was used. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were implicitly imputed by MMRM. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	327		
Units: microns				
arithmetic mean (confidence interval 95%)				
Week 4	-126.5 (-132.3 to -120.6)	-113.9 (-119.8 to -108.0)		
Week 8	-138.0 (-143.7 to -132.3)	-123.8 (-129.6 to -118.0)		
Week 12	-141.7 (-147.1 to -136.3)	-129.6 (-135.0 to -124.1)		
Week 16	-143.7 (-150.3 to -137.1)	-112.9 (-119.6 to -106.2)		
Week 20	-130.9 (-136.8 to -125.0)	-132.9 (-138.8 to -126.9)		
Week 24	-130.1 (-137.1 to -123.1)	-112.2 (-119.3 to -105.2)		
Week 28	-127.3 (-134.0 to -120.6)	-130.1 (-136.9 to -123.3)		
Week 32	-138.6 (-145.8 to -131.5)	-115.3 (-122.5 to -108.1)		
Week 36	-124.6 (-131.3 to -118.0)	-135.2 (-141.9 to -128.5)		
Week 40	-142.5 (-149.3 to -135.6)	-122.5 (-129.4 to -115.6)		
Week 44	-130.9 (-136.7 to -125.1)	-141.6 (-147.6 to -135.7)		
Week 48	-135.5 (-142.3 to -128.6)	-123.9 (-130.8 to -117.0)		
Week 52	-140.9 (-146.4 to -135.3)	-139.6 (-145.3 to -134.0)		
Week 56	-138.9 (-145.7 to -132.1)	-125.6 (-132.5 to -118.6)		
Week 60	-125.9 (-132.0 to -119.7)	-142.3 (-148.6 to -136.1)		
Week 64	-143.8 (-150.3 to -137.2)	-126.0 (-132.7 to -119.3)		
Week 68	-138.0 (-143.9 to -132.2)	-138.8 (-144.8 to -132.8)		

Week 72	-140.7 (-147.3 to -134.1)	-128.8 (-135.5 to -122.0)		
Week 76	-136.1 (-142.4 to -129.7)	-139.0 (-145.4 to -132.6)		
Week 80	-144.4 (-151.1 to -137.8)	-128.7 (-135.5 to -121.9)		
Week 84	-143.5 (-149.2 to -137.8)	-143.2 (-149.1 to -137.4)		
Week 88	-145.5 (-151.6 to -139.5)	-133.3 (-139.5 to -127.1)		
Week 92	-142.1 (-148.0 to -136.1)	-143.2 (-149.3 to -137.1)		
Week 96	-146.8 (-153.1 to -140.4)	-134.7 (-141.2 to -128.2)		
Week 100	-145.0 (-151.7 to -138.3)	-146.2 (-153.1 to -139.3)		
Week 104	-149.6 (-156.3 to -142.8)	-137.4 (-144.3 to -130.5)		
Week 108	-148.5 (-154.4 to -142.6)	-148.3 (-154.4 to -142.2)		
Week 112	-152.9 (-159.2 to -146.7)	-139.1 (-145.5 to -132.7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Absence of Intraretinal Fluid in the Study Eye Over Time

End point title	Percentage of Participants with Absence of Intraretinal Fluid in the Study Eye Over Time
End point description:	
<p>Intraretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 millimetre [mm]). The weighted estimates of the percentage of participants with absence of intraretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[39]	327 ^[40]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 324, 320)	86.9 (83.5 to 90.4)	82.9 (78.9 to 87.0)		

Week 8 (n = 324, 316)	88.5 (85.2 to 91.9)	84.6 (80.7 to 88.5)		
Week 12 (n = 323, 315)	87.5 (84.0 to 91.0)	84.5 (80.6 to 88.5)		
Week 16 (n = 320, 314)	90.6 (87.5 to 93.7)	76.5 (71.9 to 81.0)		
Week 20 (n = 320, 305)	78.8 (74.5 to 83.0)	86.1 (82.3 to 89.8)		
Week 24 (n = 294, 284)	78.7 (74.2 to 83.1)	78.0 (73.4 to 82.7)		
Week 28 (n = 291, 273)	77.1 (72.4 to 81.8)	85.9 (81.8 to 89.9)		
Week 32 (n = 286, 291)	86.3 (82.5 to 90.2)	78.3 (73.6 to 82.9)		
Week 36 (n = 293, 278)	79.6 (75.0 to 84.1)	86.1 (82.1 to 90.1)		
Week 40 (n = 277, 278)	84.5 (80.3 to 88.7)	77.5 (72.7 to 82.3)		
Week 44 (n = 275, 258)	78.5 (73.7 to 83.2)	84.2 (79.9 to 88.5)		
Week 48 (n = 274, 269)	84.1 (79.8 to 88.4)	77.7 (72.8 to 82.5)		
Week 52 (n = 281, 270)	85.9 (81.9 to 89.8)	85.3 (81.1 to 89.4)		
Week 56 (n = 281, 272)	85.2 (81.1 to 89.2)	81.1 (76.6 to 85.6)		
Week 60 (n = 273, 266)	77.8 (73.0 to 82.6)	85.4 (81.2 to 89.5)		
Week 104 (n = 259, 247)	86.0 (81.9 to 90.1)	80.0 (75.1 to 84.9)		
Week 108 (n = 264, 243)	82.2 (77.7 to 86.6)	83.5 (79.0 to 88.1)		
Week 112 (n = 266, 251)	85.9 (81.8 to 90.0)	80.5 (75.7 to 85.4)		

Notes:

[39] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[40] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Absence of Subretinal Fluid in the Study Eye Over Time

End point title	Percentage of Participants with Absence of Subretinal Fluid in the Study Eye Over Time
-----------------	--

End point description:

Subretinal fluid was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[41]	327 ^[42]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 327, 319)	70.9 (66.1 to 75.7)	61.7 (56.4 to 66.9)		
Week 8 (n = 323, 319)	79.8 (75.6 to 84.1)	73.6 (68.9 to 78.4)		
Week 12 (n = 324, 315)	88.6 (85.1 to 92.0)	79.6 (75.3 to 84.0)		
Week 16 (n = 320, 315)	90.6 (87.4 to 93.8)	63.8 (58.6 to 68.9)		
Week 20 (n = 320, 308)	76.1 (71.6 to 80.7)	80.4 (76.1 to 84.8)		
Week 24 (n = 295, 287)	73.7 (68.8 to 78.5)	59.1 (53.5 to 64.6)		
Week 28 (n = 292, 272)	71.5 (66.6 to 76.4)	78.7 (73.9 to 83.5)		
Week 32 (n = 287, 291)	82.6 (78.3 to 87.0)	62.2 (56.7 to 67.7)		
Week 36 (n = 293, 282)	70.6 (65.5 to 75.7)	80.7 (76.1 to 85.2)		
Week 40 (n = 283, 285)	77.6 (72.9 to 82.3)	63.9 (58.4 to 69.5)		
Week 44 (n = 280, 269)	65.7 (60.3 to 71.0)	76.2 (71.1 to 81.2)		
Week 48 (n = 278, 274)	72.5 (67.5 to 77.5)	62.1 (56.5 to 67.7)		
Week 52 (n = 281, 271)	83.0 (78.8 to 87.3)	80.6 (76.0 to 85.3)		
Week 56 (n = 282, 271)	80.7 (76.3 to 85.2)	71.6 (66.4 to 76.8)		
Week 60 (n = 278, 271)	63.6 (58.1 to 69.0)	80.0 (75.3 to 84.8)		
Week 104 (n = 262, 248)	80.0 (75.3 to 84.7)	73.9 (68.5 to 79.3)		
Week 108 (n = 266, 244)	76.1 (71.2 to 81.0)	80.7 (75.8 to 85.5)		
Week 112 (n = 267, 252)	80.9 (76.4 to 85.4)	77.5 (72.4 to 82.6)		

Notes:

[41] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[42] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time

End point title	Percentage of Participants with Absence of Intraretinal Fluid and Subretinal Fluid in the Study Eye Over Time
-----------------	---

End point description:

Intraretinal fluid and subretinal fluid were measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of intraretinal and subretinal fluid were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[43]	327 ^[44]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 324, 319)	59.5 (54.2 to 64.8)	49.8 (44.4 to 55.2)		
Week 8 (n = 323, 315)	70.2 (65.2 to 75.1)	61.6 (56.3 to 66.9)		
Week 12 (n = 323, 315)	77.0 (72.4 to 81.5)	66.6 (61.5 to 71.7)		
Week 16 (n = 319, 315)	82.4 (78.3 to 86.5)	47.6 (42.2 to 53.0)		
Week 20 (n = 320, 305)	62.3 (57.3 to 67.4)	68.6 (63.6 to 73.7)		
Week 24 (n = 295, 284)	56.5 (50.8 to 62.1)	45.4 (39.7 to 51.1)		
Week 28 (n = 291, 273)	55.5 (49.9 to 61.1)	66.5 (61.0 to 72.0)		
Week 32 (n = 286, 291)	73.1 (68.0 to 78.1)	48.6 (42.9 to 54.3)		
Week 36 (n = 293, 278)	56.3 (50.8 to 61.9)	68.3 (62.9 to 73.7)		
Week 40 (n = 278, 281)	65.8 (60.3 to 71.2)	49.0 (43.2 to 54.8)		
Week 44 (n = 277, 262)	49.5 (43.7 to 55.3)	64.3 (58.5 to 70.0)		
Week 48 (n = 277, 270)	62.2 (56.6 to 67.8)	46.1 (40.3 to 52.0)		
Week 52 (n = 281, 270)	70.3 (65.2 to 75.5)	68.8 (63.4 to 74.3)		
Week 56 (n = 281, 272)	66.9 (61.5 to 72.3)	57.5 (51.8 to 63.3)		
Week 60 (n = 275, 266)	49.3 (43.5 to 55.0)	69.1 (63.6 to 74.6)		
Week 104 (n = 259, 247)	68.1 (62.5 to 73.7)	58.6 (52.7 to 64.6)		
Week 108 (n = 264, 243)	61.6 (55.9 to 67.3)	67.1 (61.3 to 72.9)		
Week 112 (n = 266, 251)	68.7 (63.3 to 74.1)	61.1 (55.1 to 67.1)		

Notes:

[43] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[44] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Absence of Pigment Epithelial Detachment in the Study Eye Over Time

End point title	Percentage of Participants with Absence of Pigment Epithelial Detachment in the Study Eye Over Time
End point description:	Pigment epithelial detachment was measured using optical coherence tomography (OCT) in the central subfield (center 1 mm). The weighted estimates of the percentage of participants with absence of pigment epithelial detachment were based on the Cochran-Mantel Haenszel (CMH) weights stratified by baseline BCVA (≥ 74 letters, 73-55 letters, and ≤ 54 letters), baseline LLD (≥ 33 letters and < 33 letters), and region (U.S. and Canada vs. rest of the world). Asia and rest of the world regions were combined due to a small number of enrolled participants. Treatment policy strategy (i.e., all observed values used) and hypothetical strategy (i.e., all values censored after the occurrence of the intercurrent event) were applied to non-COVID-19 related and COVID-19 related intercurrent events, respectively. Missing data were not imputed. 95% confidence interval (CI) is a rounding of 95.03% CI.
End point type	Secondary
End point timeframe:	Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 104, 108, and 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331 ^[45]	327 ^[46]		
Units: Percentage of participants				
number (confidence interval 95%)				
Week 4 (n = 323, 320)	3.7 (1.7 to 5.8)	5.6 (3.1 to 8.1)		
Week 8 (n = 321, 318)	3.1 (1.3 to 5.0)	4.1 (1.9 to 6.2)		
Week 12 (n = 321, 314)	4.7 (2.4 to 7.0)	5.5 (3.0 to 8.0)		
Week 16 (n = 316, 313)	2.5 (0.8 to 4.1)	5.8 (3.2 to 8.4)		
Week 20 (n = 316, 306)	3.8 (1.7 to 5.9)	6.0 (3.4 to 8.6)		
Week 24 (n = 293, 284)	4.1 (1.8 to 6.3)	4.9 (2.5 to 7.4)		
Week 28 (n = 292, 273)	2.6 (0.9 to 4.4)	1.9 (0.3 to 3.5)		
Week 32 (n = 287, 291)	4.3 (2.0 to 6.6)	1.8 (0.3 to 3.3)		
Week 36 (n = 293, 283)	4.8 (2.4 to 7.1)	3.9 (1.7 to 6.1)		
Week 40 (n = 284, 286)	6.3 (3.5 to 9.0)	7.3 (4.4 to 10.3)		
Week 44 (n = 282, 270)	3.9 (1.7 to 6.2)	9.1 (5.9 to 12.4)		
Week 48 (n = 280, 275)	3.3 (1.2 to 5.3)	6.5 (3.7 to 9.3)		
Week 52 (n = 273, 267)	5.8 (3.1 to 8.5)	8.1 (5.0 to 11.3)		
Week 56 (n = 272, 266)	4.7 (2.3 to 7.2)	5.2 (2.7 to 7.7)		
Week 60 (n = 278, 271)	3.5 (1.4 to 5.6)	6.3 (3.4 to 9.1)		

Week 104 (n = 260, 246)	8.0 (4.8 to 11.2)	8.3 (5.0 to 11.7)		
Week 108 (n = 264, 244)	6.9 (3.9 to 10.0)	8.0 (4.7 to 11.2)		
Week 112 (n = 264, 248)	8.1 (4.9 to 11.3)	12.5 (8.4 to 16.5)		

Notes:

[45] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

[46] - The 'n' analyzed indicates subjects with a non-missing, valid assessment at a given timepoint.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Absence of Intraretinal Cysts in the Study Eye Over Time

End point title	Percentage of Participants with Absence of Intraretinal Cysts in the Study Eye Over Time
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 112 weeks

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[47]	0 ^[48]		
Units: Percentage of participants				
number (confidence interval 95%)	(to)	(to)		

Notes:

[47] - Not evaluated; absence of intraretinal (IR) fluid and IR cysts are described by the same variable.

[48] - Not evaluated; absence of intraretinal (IR) fluid and IR cysts are described by the same variable.

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48

End point title	Change from Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 48
-----------------	---

End point description:

The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 48

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	240	236		
Units: millimetres squared (mm ²)				
arithmetic mean (standard deviation)	0.3 (± 4.6)	1.1 (± 4.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112

End point title	Change from Baseline in Total Area of Choroidal Neovascularization Lesion in the Study Eye at Week 112
-----------------	--

End point description:

The total area of the choroidal neovascularization lesion in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and Week 112

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	240	224		
Units: millimetres squared (mm ²)				
arithmetic mean (standard deviation)	1.7 (± 7.5)	1.7 (± 4.2)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48

End point title	Change from Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 48
-----------------	--

End point description:

The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained

on or prior to randomization.

End point type	Secondary
End point timeframe:	
Baseline and Week 48	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	241	238		
Units: millimetres squared (mm ²)				
arithmetic mean (standard deviation)	-3.3 (± 6.6)	-2.1 (± 6.3)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112

End point title	Change from Baseline in Total Area of Choroidal Neovascularization Leakage in the Study Eye at Week 112
-----------------	---

End point description:

The total area of choroidal neovascularization leakage in the study eye was evaluated by a central reading center using fundus fluorescein angiography (FFA). Assessments were censored following COVID-19 related intercurrent events. Baseline was defined as the last available measurement obtained on or prior to randomization.

End point type	Secondary
End point timeframe:	
Baseline and Week 112	

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	239	220		
Units: millimetres squared (mm ²)				
arithmetic mean (standard deviation)	-5.3 (± 7.2)	-4.2 (± 5.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with at Least One Adverse Event

End point title	Percentage of Participants with at Least One Adverse Event
-----------------	--

End point description:

This analysis of adverse events (AEs) includes both ocular and non-ocular (systemic) AEs and is conducted on the safety-evaluable population. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. AEs of special interest included the following: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law; Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥ 30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

End point type Secondary

End point timeframe:

From first dose of study drug through end of study (up to 112 weeks)

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	326		
Units: Percentage of participants				
number (not applicable)				
Adverse Event (AE)	84.9	88.0		
Serious AE (SAE)	27.5	31.0		
AE Leading to Withdrawal from Study Treatment	4.8	2.8		
AE of Special Interest (AESI)	7.3	6.1		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

End point title Percentage of Participants with at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye

End point description:

This analysis of adverse events (AEs) is conducted on the safety-evaluable population, which includes all participants who received at least one dose of active study drug (faricimab or aflibercept) in the study eye. It only includes ocular AEs, which are categorized as having occurred either in the study eye or the fellow eye. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. Ocular AEs of special interest included the following: Suspected transmission of an infectious agent by the study drug; Sight-threatening AEs that cause a drop in visual acuity (VA) score ≥ 30 letters lasting more than 1 hour, require surgical or medical intervention to prevent permanent loss of sight, or are associated with severe intraocular inflammation (IOI).

End point type Secondary

End point timeframe:

From first dose of study drug through end of study (up to 112 weeks)

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	326		
Units: Percentage of participants				
number (not applicable)				
Study Eye: Adverse Event (AE)	52.9	47.5		
Study Eye: Serious AE (SAE)	4.5	4.9		
Study Eye: AE Leading to Withdrawal from Treatment	3.3	1.8		
Study Eye: Treatment-related AE	3.6	3.1		
Study Eye: Treatment-related SAE	1.8	0.6		
Study Eye: AE of Special Interest (AESI)	3.9	4.3		
Study Eye: AESI, Drop in VA Score \geq 30 Letters	2.7	3.1		
Study Eye: AESI, Associated with Severe IOI	0.6	0.3		
StudyEye:AESI,Interv Req to Avoid Perm Vision Loss	0.6	0.9		
StudyEye:Suspected Transm Infectious Agent by Drug	0.0	0.3		
Fellow Eye: AE	46.2	41.7		
Fellow Eye: SAE	3.6	2.5		
Fellow Eye: AESI	3.0	2.1		
Fellow Eye: AESI, Drop in VA Score \geq 30 Letters	2.1	1.8		
FellowEye:AESI,Inter Req to Avoid Perm Vision Loss	0.9	0.3		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with at Least One Non-Ocular Adverse Event

End point title	Percentage of Participants with at Least One Non-Ocular Adverse Event
-----------------	---

End point description:

This analysis of adverse events (AEs) is conducted on the safety-evaluable population, which includes all participants who received at least one dose of active study drug (faricimab or aflibercept) in the study eye. It only includes non-ocular (systemic) AEs. Multiple occurrences of the same AE in one individual are counted only once. Investigators sought information on AEs at each contact with the participants. All AEs were recorded and the investigator made an assessment of seriousness, severity, and causality of each AE. The non-ocular AE of special interest was: Cases of potential drug-induced liver injury that include an elevated ALT or AST in combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose of study drug through end of study (up to 112 weeks)

End point values	Arm A: Faricimab	Arm B: Aflibercept		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	331	326		
Units: Percentage of participants				
number (not applicable)				
Adverse Event (AE)	71.0	75.8		
Serious AE (SAE)	21.8	26.4		
AE Leading to Withdrawal from Study Treatment	1.5	0.9		
AE of Special Interest (AESI)	0.3	0.0		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentration of Faricimab Over Time

End point title	Plasma Concentration of Faricimab Over Time ^[49]
End point description:	Faricimab concentration in plasma was determined using a validated immunoassay method. This analysis only includes Arm A participants who received treatment with faricimab in the pharmacokinetic-evaluable population, which includes all safety-evaluable participants with at least one plasma sample, provided sufficient dosing information (dose and dosing time) was available. The number of participants analyzed at a given timepoint includes those with an available plasma sample and dosing information at that timepoint.
End point type	Secondary
End point timeframe:	Pre-dose at Baseline, Weeks 4, 16, 20, 48, 76, and 112
Notes:	[49] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint is only applicable to participants who were randomized to Arm A: Faricimab.

End point values	Arm A: Faricimab			
Subject group type	Reporting group			
Number of subjects analysed	331			
Units: micrograms per millilitre (µg/mL)				
arithmetic mean (standard deviation)				
Baseline (n = 321)	0.0000 (± 0.0001)			
Week 4 (n = 319)	0.0287 (± 0.0209)			
Week 16 (n = 300)	0.0333 (± 0.0250)			
Week 20 (n = 305)	0.0046 (± 0.0051)			
Week 48 (n = 273)	0.0149 (± 0.0185)			
Week 76 (n = 269)	0.0053 (± 0.0117)			
Week 112 (n = 278)	0.0119 (± 0.0149)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study

End point title	Percentage of Participants who Tested Positive for Treatment-Emergent Anti-Drug Antibodies Against Faricimab During the Study ^[50]
-----------------	---

End point description:

Anti-drug antibodies (ADAs) against fariciamb were detected in plasma using a validated bridging enzyme-linked immunosorbent assay (ELISA). The percentage of participants with treatment-emergent ADA-positive samples includes post-baseline evaluable participants with at least one treatment-induced (defined as having an ADA-negative sample or missing sample at baseline and any positive post-baseline sample) or treatment-boosted (defined as having an ADA-positive sample at baseline and any positive post-baseline sample with a titer that is equal to or greater than 4-fold baseline titer) ADA-positive sample during the study treatment period. The immunogenicity-analysis population includes all participants randomized to the faricimab arm with at least one determinant ADA assessment. Only those with at least one post-baseline ADA assessment were included in this analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose at Baseline, Weeks 4, 20, 48, 76, and 112

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint is only applicable to participants who were randomized to Arm A: Faricimab.

End point values	Arm A: Faricimab			
Subject group type	Reporting group			
Number of subjects analysed	330			
Units: Percentage of participants				
number (not applicable)				
Total Treatment-Emergent ADA-Positive	16.1			
Treatment-Induced ADA-Positive	16.1			
Treatment-Boosted ADA-Positive	0.0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug through end of study (up to 112 weeks)

Adverse event reporting additional description:

Adverse events (AEs) are reported for the safety population, which includes all participants who received at least one injection of active study drug (faricimab or aflibercept) in the study eye. For ocular AEs, the number of participants and events reported per term are combined totals of AEs that occurred in the study eye or the fellow eye.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	Arm B: Aflibercept
-----------------------	--------------------

Reporting group description:

Subjects randomized to the active comparator (Arm B) received a 2-mg dose of aflibercept that was administered intravitreally (IVT) Q8W, after 3 consecutive monthly doses during the 108-week treatment period. Subjects were to receive 15 IVT injections of aflibercept during the 108-week treatment period comprising three initiating injections (2 mg of aflibercept Q4W to Week 8), followed by 12 maintenance injections (2 mg of aflibercept Q8W at Weeks 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, 96, and 104).

Reporting group title	Arm A: Faricimab
-----------------------	------------------

Reporting group description:

Subjects randomized to Arm A received 6 mg of faricimab intravitreally (IVT) once every 4 weeks (Q4W) up to Week 12 (4 injections). At Week 20, protocol-defined assessment of disease activity required Arm A subjects with active disease to be treated with a once every 8 weeks (Q8W) dosing regimen of 6 mg of faricimab (i.e., at Weeks 20, 28, 36, 44, 52, and 60). A second assessment of disease activity at Week 24 required Arm A subjects with active disease (excluding those with active disease at Week 20) to be treated with a once every 12 weeks (Q12W) dosing regimen of 6 mg of faricimab IVT (i.e., at Weeks 24, 36, 48, and 60). Subjects who did not have active disease at Weeks 20 and 24 were treated with 6 mg of faricimab IVT once every 16 weeks (Q16W; i.e., at Weeks 28, 44, and 60). From Week 60 (when all of Arm A was scheduled to receive study drug) to Week 108, Arm A subjects were to be treated according to a personalized treatment interval (PTI) dosing regimen (Q8W, Q12W, or Q16W).

Serious adverse events	Arm B: Aflibercept	Arm A: Faricimab	
Total subjects affected by serious adverse events			
subjects affected / exposed	101 / 326 (30.98%)	91 / 331 (27.49%)	
number of deaths (all causes)	14	10	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon adenoma			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			

subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Bile duct cancer		
subjects affected / exposed	2 / 326 (0.61%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Extranodal marginal zone B-cell lymphoma (MALT type)		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Lung neoplasm malignant		
subjects affected / exposed	0 / 326 (0.00%)	3 / 331 (0.91%)
occurrences causally related to treatment / all	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1
Lung cancer metastatic		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Glioblastoma multiforme		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Metastases to liver		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Ovarian cancer metastatic		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pancreatic carcinoma		

subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sarcomatoid carcinoma			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sarcomatoid carcinoma of the lung			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Basal cell carcinoma			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic neoplasm			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colon cancer stage IV			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cerebral haemangioma			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin cancer			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer			

subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasm			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Adenocarcinoma of colon			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer			
subjects affected / exposed	2 / 326 (0.61%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tongue neoplasm malignant stage unspecified			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			

subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematoma			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	2 / 326 (0.61%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 2	
Pain			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ill-defined disorder			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Asthenia			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	2 / 326 (0.61%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Prostatomegaly			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic disorder			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Bronchiectasis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthma			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 326 (0.61%)	3 / 331 (0.91%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	4 / 326 (1.23%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung perforation			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pneumonitis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary artery thrombosis			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	3 / 326 (0.92%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Psychiatric disorders			
Mixed anxiety and depressive disorder			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anxiety			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device malfunction			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Investigations			
Intraocular pressure increased			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Facial bones fracture			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asbestosis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	3 / 326 (0.92%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hip fracture			
subjects affected / exposed	1 / 326 (0.31%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Rib fracture			
subjects affected / exposed	2 / 326 (0.61%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alcohol poisoning			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract operation complication			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Comminuted fracture			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Foot fracture			

subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyphaema			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract traumatic			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			
subjects affected / exposed	1 / 326 (0.31%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	1 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	3 / 326 (0.92%)	3 / 331 (0.91%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			

subjects affected / exposed	3 / 326 (0.92%)	2 / 331 (0.60%)
occurrences causally related to treatment / all	0 / 3	1 / 2
deaths causally related to treatment / all	0 / 2	0 / 1
Cardiac failure congestive		
subjects affected / exposed	6 / 326 (1.84%)	3 / 331 (0.91%)
occurrences causally related to treatment / all	0 / 11	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
Cardiopulmonary failure		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
Congestive cardiomyopathy		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Coronary artery disease		
subjects affected / exposed	3 / 326 (0.92%)	2 / 331 (0.60%)
occurrences causally related to treatment / all	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Dressler's syndrome		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Myocardial infarction		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Myocardial ischaemia		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Paroxysmal atrioventricular block		

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericarditis			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular extrasystoles			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure chronic			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Coronary artery occlusion			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Brain oedema			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Cerebral haemorrhage			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Cerebrovascular accident		
subjects affected / exposed	5 / 326 (1.53%)	2 / 331 (0.60%)
occurrences causally related to treatment / all	0 / 9	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Ischaemic stroke		
subjects affected / exposed	2 / 326 (0.61%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Presyncope		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Postictal paralysis		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Syncope		
subjects affected / exposed	2 / 326 (0.61%)	2 / 331 (0.60%)
occurrences causally related to treatment / all	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Subarachnoid haemorrhage		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1
Seizure		
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Thrombotic cerebral infarction		

subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	2 / 326 (0.61%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular dementia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Quadriplegia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dementia Alzheimer's type			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic cerebral infarction			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 326 (0.61%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Angle closure glaucoma			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cataract			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal oedema			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye allergy			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Macular degeneration			

subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neovascular age-related macular degeneration			
subjects affected / exposed	4 / 326 (1.23%)	8 / 331 (2.42%)	
occurrences causally related to treatment / all	0 / 4	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal haemorrhage			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal pigment epithelial tear			
subjects affected / exposed	0 / 326 (0.00%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 0	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal vein occlusion			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitreous haemorrhage			
subjects affected / exposed	1 / 326 (0.31%)	3 / 331 (0.91%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Uveitis			
subjects affected / exposed	2 / 326 (0.61%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	1 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitritis			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-infectious endophthalmitis			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual acuity reduced			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retinal tear			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Age-related macular degeneration			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral exudative haemorrhagic chorioretinopathy			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diplopia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dry age-related macular degeneration			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Corneal opacity			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	3 / 326 (0.92%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum intestinal			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	2 / 326 (0.61%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastric dysplasia		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Intestinal obstruction		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Abdominal pain upper		
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Oesophageal ulcer		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Food poisoning		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Large intestine perforation		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Lower gastrointestinal haemorrhage		
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Inguinal hernia		

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Biliary obstruction			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis			
subjects affected / exposed	1 / 326 (0.31%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis acute			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Cystitis haemorrhagic			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Arthritis			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fracture nonunion			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar spinal stenosis			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal stiffness			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	2 / 326 (0.61%)	4 / 331 (1.21%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhabdomyolysis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spondylolisthesis			

subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rheumatic disorder			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	4 / 326 (1.23%)	3 / 331 (0.91%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	2 / 326 (0.61%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chorioretinitis			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	2 / 326 (0.61%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endophthalmitis			
subjects affected / exposed	3 / 326 (0.92%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infectious pleural effusion			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Influenza		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Necrotising fasciitis		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Osteomyelitis		
subjects affected / exposed	1 / 326 (0.31%)	1 / 331 (0.30%)
occurrences causally related to treatment / all	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Pneumonia		
subjects affected / exposed	6 / 326 (1.84%)	2 / 331 (0.60%)
occurrences causally related to treatment / all	0 / 7	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
Pyelonephritis acute		
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Sepsis		
subjects affected / exposed	5 / 326 (1.53%)	0 / 331 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Viral uveitis		

subjects affected / exposed	0 / 326 (0.00%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	7 / 326 (2.15%)	2 / 331 (0.60%)	
occurrences causally related to treatment / all	0 / 7	0 / 2	
deaths causally related to treatment / all	0 / 2	0 / 0	
Endocarditis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 326 (0.00%)	1 / 331 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vestibular neuronitis			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vitamin B12 deficiency			

subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gout			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypervolaemia			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 326 (0.31%)	0 / 331 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm B: Aflibercept	Arm A: Faricimab	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	165 / 326 (50.61%)	178 / 331 (53.78%)	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	22 / 326 (6.75%)	18 / 331 (5.44%)	
occurrences (all)	27	20	
Vascular disorders			
Hypertension			
subjects affected / exposed	18 / 326 (5.52%)	15 / 331 (4.53%)	
occurrences (all)	18	15	
Eye disorders			

Conjunctival haemorrhage subjects affected / exposed occurrences (all)	37 / 326 (11.35%) 72	35 / 331 (10.57%) 47	
Neovascular age-related macular degeneration subjects affected / exposed occurrences (all)	62 / 326 (19.02%) 81	80 / 331 (24.17%) 103	
Dry eye subjects affected / exposed occurrences (all)	21 / 326 (6.44%) 37	15 / 331 (4.53%) 27	
Cataract subjects affected / exposed occurrences (all)	26 / 326 (7.98%) 38	38 / 331 (11.48%) 55	
Vitreous detachment subjects affected / exposed occurrences (all)	21 / 326 (6.44%) 26	22 / 331 (6.65%) 29	
Posterior capsule opacification subjects affected / exposed occurrences (all)	19 / 326 (5.83%) 23	15 / 331 (4.53%) 20	
Infections and infestations			
Nasopharyngitis subjects affected / exposed occurrences (all)	22 / 326 (6.75%) 25	27 / 331 (8.16%) 33	
Urinary tract infection subjects affected / exposed occurrences (all)	29 / 326 (8.90%) 36	19 / 331 (5.74%) 23	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 February 2019	Protocol Version 2: Amended to address feedback from the Voluntary Harmonisation Procedure. To enhance patient safety and to comply with health authority requests, patients with a known hypersensitivity to fluorescein were excluded. Also, the criterion for interruption and resuming study treatment after IOI was amended for clarity.
06 August 2019	Protocol Version 3: -The criteria for the extension of the drug-dosing interval during the PTI phase was changed from a qualitative assessment of the presence of fluid to a quantitative assessment of CST stability.; -The study-eye inclusion criteria were amended to include patients with extrafoveal CNV membranes with a subfoveal component, secondary to nAMD.; -To ensure appropriate patient representation, the Sponsor could elect to cap the recruitment of patients in certain baseline BCVA strata.; -Reporting of medication errors and associated AE was updated. Medication errors were no longer to be reported expeditiously (within 24 hours), unless they caused a SAE or AESI. -As applicable throughout the protocol, the term "free" was added before VEGF-A and Ang-2 to more accurately describe what the assays were measuring and to be consistent with the other sections of the protocol.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported